Telix Pharmaceuticals Limited Stock 12‑Month Price Target Cut to $17.95, Implies 61% Upside

Telix Pharmaceuticals' shares fell 10% despite 19% revenue growth in Q3, with Precision Medicine unit revenue up 30%. The company launched Pixclara and expects full-year revenue to exceed $1 billion. Analysts remain positive, but investors reacted negatively to the lack of growth acceleration and concerns over the ITM merger.

Telix Pharmaceuticals reported 1% U.S. dose volume growth for Gozellix and Illuccix in Q3 2026, FDA approval for Pixclara, and a planned merger with ITM. The company reaffirmed its 2026 Precision Medicine revenue growth target of over 25%.

Telix Pharmaceuticals reported Q3 2026 revenue of $245M, up 19% YoY, driven by strong demand for its PSMA products. Precision Medicine revenue grew 30% to $201M. The FDA approved Pixclara for glioma imaging, and the company completed BiPASS study enrollment. Telix also announced a merger with ITM, expecting FY 2026 revenue to exceed $1B.

Telix Pharmaceuticals (TLX) reported Q3 2026 results, highlighting strong U.S. dose volumes and reaffirming its outlook for over 25% Precision Medicine revenue growth. The company received FDA approval for Pixclara and announced a merger with ITM. Figures are unaudited.

Telix Pharmaceuticals and Ekalia (a joint venture between IBA and Framatome) are collaborating to establish U.S. production of astatine-211 (211At), a rare radioisotope for cancer treatment. The partnership will use IBA's cyclotron technology and Telix's U.S. radiopharmacy infrastructure. Telix aims to advance its alpha therapy pipeline, including TLX102-Tx for glioblastoma, and support third-party research.

The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.